11 June 2024 - Approval in patients with pJIA weighing 63 kg or greater adds to Kevzara’s position in treating adult chronic inflammatory conditions of moderately to severely active rheumatoid arthritis and polymyalgia rheumatica.

Regeneron Pharmaceuticals and Sanofi today announced that the US FDA has approved Kevzara (sarilumab) for the treatment of patients weighing 63 kg or greater with active polyarticular juvenile idiopathic arthritis, a form of arthritis that impacts multiple joints at a time.

Read Regeneron Pharmaceuticals press release